{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:36:00Z","timestamp":1794274560342,"version":"4.9.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"am","delay-in-days":353,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019637","name":"Horizon Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019637","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 026877"],"award-info":[{"award-number":["P30 026877"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ophtha.2023.10.018","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T20:49:15Z","timestamp":1697489355000},"page":"458-467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Teprotumumab-Related Adverse Events in Thyroid Eye Disease"],"prefix":"10.1016","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7055-7566","authenticated-orcid":false,"given":"Shreya A.","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linus","family":"Amarikwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie M.","family":"Sears","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin D.","family":"Clauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raneem D.","family":"Rajjoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Y.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhura A.","family":"Tamhankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar A.","family":"Brice\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysoula","family":"Dosiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly P.","family":"Cockerham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara T.","family":"Wester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond S.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3110-1210","authenticated-orcid":false,"given":"Andrea L.","family":"Kossler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ophtha.2023.10.018_bib1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1161\/01.ATV.0000105902.89459.09","article-title":"Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels","volume":"24","author":"Delafontaine","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.ophtha.2023.10.018_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/IOP.0000000000002146","article-title":"The role of insulin-like growth factor-1 and its receptor in the eye: a review and implications for IGF-1R inhibition","volume":"39","author":"Truong","year":"2023","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"3","key":"10.1016\/j.ophtha.2023.10.018_bib4","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1523\/JNEUROSCI.1700-08.2009","article-title":"Insulin-like growth factor-1 promotes G1\/S cell cycle progression through bidirectional regulation of cyclins and cyclin-dependent kinase inhibitors via the phosphatidylinositol 3-kinase\/Akt pathway in developing rat cerebral cortex","volume":"29","author":"Mairet-Coello","year":"2009","journal-title":"J\u00a0Neurosci"},{"issue":"4","key":"10.1016\/j.ophtha.2023.10.018_bib5","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.cytogfr.2006.02.002","article-title":"Regulation of apoptosis by insulin-like growth factor (IGF)-I","volume":"17","author":"Kooijman","year":"2006","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4","key":"10.1016\/j.ophtha.2023.10.018_bib6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ophtha.2023.10.018_bib7","doi-asserted-by":"crossref","first-page":"bvab034","DOI":"10.1210\/jendso\/bvab034","article-title":"Thyroid eye disease: navigating the new treatment landscape","volume":"5","author":"Dosiou","year":"2021","journal-title":"J\u00a0Endocr Soc"},{"key":"10.1016\/j.ophtha.2023.10.018_bib8","unstructured":"American Thyroid Association. Clinical Thyroidology for the Public. August 2021;14(8):5\u20136. Available at: https:\/\/www.thyroid.org\/patient-thyroid-information\/ct-for-patients\/august-2021\/vol-14-issue-8-p-5-6\/; Accessed August 18, 2022."},{"issue":"18","key":"10.1016\/j.ophtha.2023.10.018_bib9","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ophtha.2023.10.018_bib10","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves\u2019 ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ophtha.2023.10.018_bib11","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5732\/cjc.012.10263","article-title":"IGF-1R as an anti-cancer target\u2014trials and tribulations","volume":"32","author":"Chen","year":"2013","journal-title":"Chin J Cancer"},{"issue":"11","key":"10.1016\/j.ophtha.2023.10.018_bib12","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ophtha.2021.04.024","article-title":"Teprotumumab: interpreting the clinical trials in the context of thyroid eye disease pathogenesis and current therapies","volume":"128","author":"Winn","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2023.10.018_bib13","doi-asserted-by":"crossref","unstructured":"Kahaly GJ, Douglas RS, Holt RJ, et al. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol. Published online April 15, 2021. https:\/\/doi.org\/10.1016\/s2213-8587(21)00056-5.","DOI":"10.1016\/S2213-8587(21)00056-5"},{"key":"10.1016\/j.ophtha.2023.10.018_bib14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.heares.2019.01.008","article-title":"Insulin-like growth factor 1 promotes cochlear synapse regeneration after excitotoxic trauma in\u00a0vitro","volume":"374","author":"Yamahara","year":"2019","journal-title":"Hear Res"},{"issue":"1\u20132","key":"10.1016\/j.ophtha.2023.10.018_bib15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.heares.2003.12.022","article-title":"Trophic effects of insulin-like growth factor-I (IGF-I) in the inner ear","volume":"196","author":"Varela-Nieto","year":"2004","journal-title":"Hear Res"},{"issue":"2","key":"10.1016\/j.ophtha.2023.10.018_bib16","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1460-9568.2005.04584.x","article-title":"Sensorineural hearing loss in insulin-like growth factor I-null mice: a new model of human deafness","volume":"23","author":"Cediel","year":"2006","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.ophtha.2023.10.018_bib17","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3389\/fnagi.2017.00411","article-title":"The role of insulin-like growth factor 1 in the progression of age-related hearing loss","volume":"9","author":"Rodr\u00edguez-de la Rosa","year":"2017","journal-title":"Front Aging Neurosci"},{"issue":"1\u20132","key":"10.1016\/j.ophtha.2023.10.018_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0378-5955(00)00040-X","article-title":"Ear and hearing in relation to genotype and growth in Turner syndrome","volume":"144","author":"Barren\u00e4s","year":"2000","journal-title":"Hear Res"},{"issue":"2","key":"10.1016\/j.ophtha.2023.10.018_bib19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00405-011-1668-x","article-title":"Cochlear hearing loss in patients with Laron syndrome","volume":"269","author":"Attias","year":"2012","journal-title":"Eur Arch Oto-Rhino-Laryngol"},{"issue":"2","key":"10.1016\/j.ophtha.2023.10.018_bib20","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1053\/j.gastro.2006.05.055","article-title":"The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice","volume":"131","author":"Dube","year":"2006","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.ophtha.2023.10.018_bib21","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/ncpendmet0427","article-title":"Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1","volume":"3","author":"LeRoith","year":"2007","journal-title":"Nat Clin Pr Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.ophtha.2023.10.018_bib22","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.3390\/cells9091970","article-title":"Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy","volume":"9","author":"Yoshida","year":"2020","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.ophtha.2023.10.018_bib24","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1001\/archinte.165.12.1363","article-title":"Adverse drug event surveillance and drug withdrawals in the United States, 1969\u20132002: the importance of reporting suspected reactions","volume":"165","author":"Wysowski","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ophtha.2023.10.018_bib27","author":"Prutsman"},{"key":"10.1016\/j.ophtha.2023.10.018_bib28","article-title":"A\u00a0case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease","volume":"22","author":"Safo","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"5","key":"10.1016\/j.ophtha.2023.10.018_bib29","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1097\/IOP.0000000000001943","article-title":"New-onset of inflammatory bowel disease in a patient treated with teprotumumab for thyroid associated ophthalmopathy","volume":"37","author":"Ashraf","year":"2021","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"4","key":"10.1016\/j.ophtha.2023.10.018_bib30","first-page":"148","article-title":"A\u00a0novel case of hyperglycemic hyperosmolar state after the use of teprotumumab in a patient with thyroid eye disease","volume":"8","author":"Shah","year":"2022","journal-title":"AACE Clin Case Rep"},{"key":"10.1016\/j.ophtha.2023.10.018_bib31","doi-asserted-by":"crossref","unstructured":"Amarikwa L, Mohamed A, Kim SH, et\u00a0al. Teprotumumab-related hyperglycemia [published online October 27, 2022]. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgac627.","DOI":"10.1210\/clinem\/dgac627"},{"key":"10.1016\/j.ophtha.2023.10.018_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2022.02.015","article-title":"Hearing dysfunction after treatment with teprotumumab for thyroid eye disease","volume":"240","author":"Sears","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ophtha.2023.10.018_bib33","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/s41433-021-01593-z","article-title":"Teprotumumab for the treatment of chronic thyroid eye disease","volume":"36","author":"Ugradar","year":"2022","journal-title":"Eye"},{"key":"10.1016\/j.ophtha.2023.10.018_bib34","article-title":"Early experience with teprotumumab for chronic thyroid eye disease","volume":"19","author":"Ozzello","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.ophtha.2023.10.018_bib36","series-title":"StatPearls. StatPearls Publishing","article-title":"Dysthyroid optic neuropathy","author":"Agarwal","year":"2022"},{"issue":"3","key":"10.1016\/j.ophtha.2023.10.018_bib37","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/eye.2012.284","article-title":"Acute thyroid eye disease (TED): principles of medical and surgical management","volume":"27","author":"Verity","year":"2013","journal-title":"Eye"},{"key":"10.1016\/j.ophtha.2023.10.018_bib38","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2147\/TCRM.S303057","article-title":"Efficacy and safety of teprotumumab in thyroid eye disease","volume":"17","author":"Teo","year":"2021","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"10.1016\/j.ophtha.2023.10.018_bib40","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/WNO.0000000000001134","article-title":"Teprotumumab in clinical practice: recommendations and considerations from the OPTIC Trial Investigators","volume":"41","author":"Douglas","year":"2021","journal-title":"J\u00a0Neuroophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642023007601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642023007601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T10:58:11Z","timestamp":1778669891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642023007601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0161642023007601"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2023.10.018","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Teprotumumab-Related Adverse Events in Thyroid Eye Disease","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2023.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}